Review ArticleReview

Modulating microRNAs in cancer: next-generation therapies

Nahid Arghiani and Khalid Shah
Cancer Biology & Medicine March 2022, 19 (3) 289-304; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0294

References

  1. 1.↵
    2. Anglicheau D,
    3. Muthukumar T,
    4. Suthanthiran M.
    MicroRNAs: small RNAs with big effects. Transplantation. 2010; 90: 105–12.
    OpenUrlPubMedWeb of Science
  2. 2.↵
    2. Martinez VD,
    3. Cohn DE,
    4. Telkar N,
    5. Minatel BC,
    6. Pewarchuk ME,
    7. Marshall EA, et al.
    Profiling the small non-coding RNA transcriptome of the human placenta. Sci Data. 2021; 8: 166.
    OpenUrl
  3. 3.↵
    2. Peng Y,
    3. Croce CM.
    The role of microRNAs in human cancer. Signal Transduct Target Ther. 2016; 1: 15004.
  4. 4.↵
    2. Walayat A,
    3. Yang M,
    4. Xiao D
    2. Sharad S,
    3. Kapur S.
    Therapeutic implication of miRNA in human disease. In: Walayat A, Yang M, Xiao D, editors. Antisense Therapy. London: IntechOpen; 2018. p. 82738.
  5. 5.↵
    2. Hata A,
    3. Lieberman J.
    Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 2015; 8: re3.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    2. Iorio MV,
    3. Croce CM.
    Causes and consequences of microRNA dysregulation. Cancer J. 2012; 18: 215–22.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Zeinali T,
    3. Mansoori B,
    4. Mohammadi A,
    5. Baradaran B.
    Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomed Pharmacother. 2019; 109: 195–207.
    OpenUrl
  8. 8.↵
    2. Wang B,
    3. Hsu SH,
    4. Wang X,
    5. Kutay H,
    6. Bid HK,
    7. Yu J, et al.
    Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2. Hepatology. 2014; 59: 555–66.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Misiewicz-Krzeminska I,
    3. Krzeminski P,
    4. Corchete LA,
    5. Quwainder D,
    6. Rojas EA,
    7. Herreero AB, et al.
    Factors regulating microRNA expression and function in multiple myeloma. Noncoding RNA. 2019; 5: 9.
    OpenUrl
  10. 10.↵
    2. Xiao J,
    3. Lin H,
    4. Luo X,
    5. Luo X,
    6. Wang Z.
    MiR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J. 2011; 30: 5021.
    OpenUrlFREE Full Text
  11. 11.↵
    2. Hermeking H.
    The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010; 17: 193–9.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Ma J,
    3. Gong W,
    4. Liu S,
    5. Li Q,
    6. Guo M,
    7. Wang J, et al.
    Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3. Tumour Biol. 2018; 40: 1010428317731369.
  13. 13.↵
    2. Kent OA,
    3. Chivukula RR,
    4. Mullendore M,
    5. Wentzel EA,
    6. Feldmann G,
    7. Lee KL, et al.
    Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010; 24: 2754–9.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    2. Bracken CP,
    3. Gregory PA,
    4. Kolesnikoff N,
    5. Bert AG,
    6. Wang J,
    7. Shannon MF, et al.
    A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008; 68: 7846–54.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    2. Jiang RL,
    3. Li Y.
    Regulation of miRNA pathway and roles of microRNAs in tumorigenesis and metastasis. Human Genet Embryol S. 2013; 2: 2161–436.
    OpenUrl
  16. 16.↵
    2. Kim J,
    3. Yao F,
    4. Xiao Z,
    5. Sun Y,
    6. Ma L.
    MicroRNAs and metastasis: small RNAs play big roles. Cancer Metastasis Rev. 2018; 37: 5–15.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Yoshida K,
    3. Yamamoto Y,
    4. Ochiya T.
    MiRNA signaling networks in cancer stem cells. Regen Ther. 2021; 17: 1–7.
    OpenUrl
  18. 18.↵
    2. Diepenbruck M,
    3. Tiede S,
    4. Saxena M,
    5. Ivanek R,
    6. Kalathur RKR,
    7. Lüönd F, et al.
    MiR-1199-5p and Zeb1 function in a double-negative feedback loop potentially coordinating EMT and tumour metastasis. Nat Commun. 2017; 8: 1168.
    OpenUrl
  19. 19.↵
    2. Zhu X,
    3. Pan H,
    4. Liu L.
    Long noncoding RNA network: Novel insight into hepatocellular carcinoma metastasis (Review). Int J Mol Med. 2021; 48: 1–12.
    OpenUrl
  20. 20.↵
    2. Arghiani N,
    3. Matin MM.
    MiR-21: A key small molecule with great effects in combination cancer therapy. Nucleic Acid Ther. 2021; 31: 271–83.
    OpenUrl
  21. 21.↵
    2. Cai Z,
    3. Zhang F,
    4. Chen W,
    5. Zhang J,
    6. Li H.
    MiRNAs: A promising target in the chemoresistance of bladder cancer. Onco Targets Ther. 2019; 12: 11805–16.
    OpenUrl
  22. 22.↵
    2. An X,
    3. Sarmiento C,
    4. Tan T,
    5. Zhu H.
    Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017; 7: 38–51.
    OpenUrl
  23. 23.↵
    2. Jamialahmadi K,
    3. Zahedipour F,
    4. Karimi G.
    The role of microRNAs on doxorubicin drug resistance in breast cancer. J Pharm Pharmacol. 2021; 73: 997–1006.
    OpenUrl
  24. 24.↵
    2. Tian Y,
    3. Tang L,
    4. Yi P,
    5. Pan Q,
    6. Han Y,
    7. Shi Y, et al.
    MiRNAs in radiotherapy resistance of nasopharyngeal carcinoma. J Cancer. 2020; 11: 3976–85.
    OpenUrl
  25. 25.↵
    2. Li D,
    3. Tolleson WH,
    4. Yu D,
    5. Chen S,
    6. Guo L,
    7. Xiao W, et al.
    Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2019; 37: 180–214.
    OpenUrl
  26. 26.↵
    2. Lan H,
    3. Lu H,
    4. Wang X,
    5. Jin H.
    MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015; 2015: 125094.
  27. 27.↵
    2. Arneth B.
    Tumor microenvironment. Medicina. 2019; 56: 15.
    OpenUrl
  28. 28.↵
    2. Caner A,
    3. Asik E,
    4. Ozpolat B.
    SRC signaling in cancer and tumor microenvironment. Adv Exp Med Biol. 2021; 1270: 57–71.
    OpenUrl
  29. 29.↵
    2. Antomarchi J,
    3. Ambrosetti D,
    4. Cohen C,
    5. Delotte J,
    6. Chevallier A,
    7. Karimdjee-Soilihi B, et al.
    Immunosuppressive tumor microenvironment status and histological grading of endometrial carcinoma. Cancer Microenviron. 2019; 12: 169–79.
    OpenUrl
  30. 30.↵
    2. Avraham R,
    3. Yarden Y.
    Regulation of signalling by microRNAs. Biochem Soc Trans. 2012; 40: 26–30.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    2. Eichelmann AK,
    3. Matuszcak C,
    4. Hummel R,
    5. Haier J.
    Role of miRNAs in cell signaling of cancer associated fibroblasts. Int J Biochem Cell Biol. 2018; 101: 94–102.
    OpenUrlCrossRef
  32. 32.↵
    2. Boguslawska J,
    3. Kryst P,
    4. Poletajew S,
    5. Piekielko-Witkowska A.
    TGF-β and microRNA Interplay in genitourinary cancers. Cells. 2019; 8: 1619.
    OpenUrl
  33. 33.↵
    2. Wang R,
    3. Sun Y,
    4. Yu W,
    5. Yan Y,
    6. Qiao M,
    7. Jiang R, et al.
    Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT. J Exp Clin Cancer Res. 2019; 38: 20.
    OpenUrl
  34. 34.↵
    2. Musumeci M,
    3. Coppola V,
    4. Addario A,
    5. Patrizii M,
    6. Maugeri-Sacca M,
    7. Memeo L, et al.
    Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 2011; 30: 4231–42.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    2. Loh HY,
    3. Norman BP,
    4. Lai KS,
    5. Rahman NM,
    6. Alitheen NB,
    7. Osman MA.
    The regulatory role of microRNAs in breast cancer. Int J Mol Sci. 2019; 20: 4940.
    OpenUrlCrossRefPubMed
  36. 36.
    2. Lou W,
    3. Liu J,
    4. Gao Y,
    5. Zhong G,
    6. Chen D,
    7. Shen J, et al.
    MicroRNAs in cancer metastasis and angiogenesis. Oncotarget. 2017; 8: 115787–802.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Wang H,
    3. Li K,
    4. Mei Y,
    5. Huang X,
    6. Li Z,
    7. Yang Q, et al.
    Sp1 suppresses miR-3178 to promote the metastasis invasion cascade via upregulation of TRIOBP. Mol Ther Nucleic Acids. 2018; 12: 1–11.
    OpenUrlCrossRef
  38. 38.↵
    2. Yang H,
    3. Zhang H,
    4. Ge S,
    5. Nng T,
    6. Bai M,
    7. Li J, et al.
    Exosome-derived miR-130a activates angiogenesis in gastric cancer by targeting C-MYB in vascular endothelial cells. Mol Ther. 2018; 26: 2466–75.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Liu LZ,
    3. Li C,
    4. Chen Q,
    5. Jing Y,
    6. Carpenter R,
    7. Jiang Y, et al.
    MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One. 2011; 6: e19139.
  40. 40.↵
    2. Zhuang G,
    3. Wu X,
    4. Jiang Z,
    5. Kasman I,
    6. Yao J,
    7. Guan Y, et al.
    Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012; 31: 3513–23.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    2. Goradel NH,
    3. Mohammadi N,
    4. Haghi-Aminjan H,
    5. Farhood B,
    6. Negshdari B,
    7. Sahebkar A.
    Regulation of tumor angiogenesis by microRNAs: State of the art. J Cell Physiol. 2019; 234: 1099–110.
    OpenUrl
  42. 42.↵
    2. Chung HJ,
    3. Choi YE,
    4. Kim ES,
    5. Han YH,
    6. Park MJ,
    7. Bae IH.
    miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2. Oncotarget. 2015; 6: 18429–44.
    OpenUrl
  43. 43.↵
    2. Chen S,
    3. Zhang Y,
    4. Kuzel TM,
    5. Zhang B.
    Regulating tumor myeloid-derived suppressor cells by microRNAs. Cancer Cell Microenviron. 2015; 2: 1–8.
    OpenUrl
  44. 44.↵
    2. Marcinkowska M,
    3. Sobierajska E,
    4. Stanczyk M,
    5. Janaszewska A,
    6. Chworos A,
    7. Klajnert-Maculewicz B.
    Conjugate of PAMAM dendrimer, doxorubicin and monoclonal antibody-trastuzumab: the new approach of a well-known strategy. Polymers. 2018; 10: 187.
    OpenUrl
  45. 45.↵
    2. Sirotkin AV,
    3. Alexa R,
    4. Kišová G,
    5. Harrath AH,
    6. Alwasel S,
    7. Ovcharenko D, et al.
    MicroRNAs control transcription factor NF-kB (p65) expression in human ovarian cells. Funct Integr Genomics. 2015; 15: 271–5.
    OpenUrl
  46. 46.↵
    2. An Y,
    3. Yang Q.
    MiR-21 modulates the polarization of macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer. Life Sci. 2020; 242: 117162.
  47. 47.
    2. Afshar AS,
    3. Xu J,
    4. Goutsias J.
    Integrative identification of deregulated miRNA/TF-mediated gene regulatory loops and networks in prostate cancer. PLoS One. 2014; 9: e100806.
  48. 48.↵
    2. Shoeibi S.
    Diagnostic and theranostic microRNAs in the pathogenesis of atherosclerosis. Acta Physiol. 2020; 228: e13353.
  49. 49.↵
    2. Nakano T,
    3. Chen IH,
    4. Wang CC,
    5. Chen PJ,
    6. Tseng HP,
    7. Huang KT, et al.
    Circulating exosomal miR-92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence. Am J Transplant. 2019; 19: 3250–62.
    OpenUrl
  50. 50.↵
    2. Kogure A,
    3. Kosaka N,
    4. Ochiya T.
    Cross-talk between cancer cells and their neighbors via miRNA in extracellular vesicles: an emerging player in cancer metastasis. J Biomed Sci. 2019; 26: 7.
    OpenUrl
  51. 51.↵
    2. Dai X,
    3. Huang R,
    4. Hu S,
    5. Zhou Y,
    6. Sun X,
    7. Gui P, et al.
    A novel miR-0308-3p revealed by miRNA-seq of HBV-positive hepatocellular carcinoma suppresses cell proliferation and promotes G1/S arrest by targeting double CDK6/Cyclin D1 genes. Cell Biosci. 2020; 10: 24.
    OpenUrl
  52. 52.
    2. Lee WH,
    3. Chen KP,
    4. Wang K,
    5. Huang HC,
    6. Juan HF.
    Characterizing the cancer-associated microbiome with small RNA sequencing data. Biochem Biophys Res Commun. 2020; 522: 776–82.
    OpenUrl
  53. 53.
    2. Hanna J,
    3. Hossain GS,
    4. Kocerha J.
    The potential for microRNA therapeutics and clinical research. Front Genet. 2019; 10: 478.
    OpenUrlCrossRefPubMed
  54. 54.↵
    2. Kim H,
    3. Kim J,
    4. Kim K,
    5. Chang H,
    6. You K,
    7. Kim VN.
    Bias-minimized quantification of microRNA reveals widespread alternative processing and 3’ end modification. Nucleic Acids Res. 2019; 47: 2630–40.
    OpenUrlCrossRefPubMed
  55. 55.↵
    2. Wang N,
    3. Zheng J,
    4. Chen Z,
    5. Liu Y,
    6. Dura B,
    7. Kwak M, et al.
    Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation. Nat Commun. 2019; 10: 95.
    OpenUrlCrossRef
  56. 56.↵
    2. Bhere D,
    3. Arghiani N,
    4. Lechtich ER,
    5. Yao Y,
    6. Alsaab S,
    7. Bei F, et al.
    Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy. Sci Rep. 2020; 10: 1779.
    OpenUrl
  57. 57.↵
    2. Corsten MF,
    3. Miranda R,
    4. Kasmieh R,
    5. Krichevsky AM,
    6. Weissleder R,
    7. Shah K.
    MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 2007; 67: 8994–9000.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    2. Lima JF,
    3. Cerqueira L,
    4. Figueiredo C,
    5. Oliveira C,
    6. Azevedo NF.
    Anti-miRNA oligonucleotides: A comprehensive guide for design. RNA Biol. 2018; 15: 338–52.
    OpenUrl
  59. 59.↵
    2. Balacescu O,
    3. Visan S,
    4. Baldasici O,
    5. Balacescu L
    2. Sharad S,
    3. Kapur S.
    MiRNA-based therapeutics in oncology, realities, and challenges. In: Balacescu O, Visan S, Baldasici O, Balacescu L, editors. Antisense Therapy. London: IntechOpen. 2018; 31.
  60. 60.↵
    2. Zhong S,
    3. Jeong JH,
    4. Chen Z,
    5. Chen Z,
    6. Luo JL.
    Targeting tumor microenvironment by small-molecule inhibitors. Transl Oncol. 2020; 13: 57–69.
    OpenUrlCrossRef
  61. 61.↵
    2. Aquino-Jarquin G.
    Emerging role of CRISPR/Cas9 technology for microRNAs editing in cancer research. Cancer Res. 2017; 77: 6812–7.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    2. Nam L,
    3. Coll C,
    4. Erthal LCS,
    5. de la Torre C,
    6. Serrano D,
    7. Martínez-Máñez R, et al.
    Drug delivery nanosystems for the localized treatment of glioblastoma multiforme. Materials (Basel). 2018; 11: 779.
    OpenUrl
  63. 63.↵
    2. Chen Y,
    3. Gao DY,
    4. Huang L.
    In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015; 81: 128–41.
    OpenUrlCrossRefPubMed
  64. 64.↵
    2. Delcassian D,
    3. Patel AK
    2. Ladame S,
    3. Cheng JY.
    Nanotechnology and drug delivery. In: Delcassian D, Patel AK, editors. Bioengineering innovative solutions for cancer. Cambridge: Academic Press; 2020. p. 197–219.
  65. 65.↵
    2. Rietwyk S,
    3. Peer D.
    Next-generation lipids in RNA interference therapeutics. ACS Nano. 2017; 11: 7572–86.
    OpenUrl
  66. 66.
    2. Chen Y,
    3. Zhu X,
    4. Zhang X,
    5. Liu B,
    6. Huang L.
    Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010; 18: 1650–6.
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.
    2. Zhang JS,
    3. Liu F,
    4. Huang L.
    Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev. 2005; 57: 689–98.
    OpenUrlCrossRefPubMed
  68. 68.
    2. Trang P,
    3. Wiggins JF,
    4. Daige CL,
    5. Cho C,
    6. Omotola M,
    7. Brown D, et al.
    Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011; 19: 1116–22.
    OpenUrlCrossRefPubMed
  69. 69.
    2. Myoung SS,
    3. Kasinski AL
    2. Peplow PV,
    3. Martinez B,
    4. Calin GA,
    5. Esquela-Kerscher A.
    Strategies for safe and targeted delivery of microRNA therapeutics. In: Myoung SS, Kasinski AL, editors. MicroRNAs in diseases and disorders. London: Royal Society of Chemistry; 2019. p. 386–415.
  70. 70.
    2. Malik SS,
    3. Masood N,
    4. Sherrard A,
    5. Bishop PN
    2. Malik B.
    Small non-coding RNAs as a tool for personalized therapy in familial cancers. In: Malik SS, Masood N, Sherrard A, Bishop PN, editors. AGO-driven non-coding RNAs. Cambridge: Academic Press; 2019. p. 179–208.
  71. 71.
    2. Daige CL,
    3. Wiggins JF,
    4. Priddy L,
    5. Nelligan-Davis T,
    6. Zhao J,
    7. Brown D.
    Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther. 2014; 13: 2352–60.
    OpenUrlAbstract/FREE Full Text
  72. 72.
    2. Bai Z,
    3. Wei J,
    4. Yu C,
    5. Han X,
    6. Qin X,
    7. Zhanf C, et al.
    Non-viral nanocarriers for intracellular delivery of microRNA therapeutics. J Mater Chem B. 2019; 7: 1209–25.
    OpenUrl
  73. 73.↵
    2. Garg U,
    3. Chauhan S,
    4. Nagaich U,
    5. Jain N.
    Current advances in chitosan nanoparticles based drug delivery and targeting. Adv Pharm Bull. 2019; 9: 195–204.
    OpenUrl
  74. 74.
    2. Palmerston Mendes L,
    3. Pan J,
    4. Torchilin VP.
    Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017; 22: 1404.
    OpenUrl
  75. 75.
    2. Ren L,
    3. Huang C,
    4. Liu YH,
    5. Yu Y,
    6. Lin L,
    7. Wen LJ.
    The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain. Zhonghua Yi Xue Za Zhi. 2016; 96: 1454–8.
    OpenUrl
  76. 76.↵
    2. Mir M,
    3. Ahmed N,
    4. Rehman AU.
    Recent applications of PLGA based nanostructures in drug delivery. Colloid Surface B Biointerfaces. 2017; 159: 217–31.
    OpenUrl
  77. 77.↵
    2. Navarro SM,
    3. Morgan TW,
    4. Astete CE,
    5. Stout RW,
    6. Coulon D,
    7. Mottram P, et al.
    Biodistribution and toxicity of orally administered poly (lactic-co-glycolic) acid nanoparticles to F344 rats for 21 days. Nanomedicine. 2016; 11: 1653–69.
    OpenUrl
  78. 78.↵
    2. Sharma S,
    3. Parmar A,
    4. Kori S,
    5. Sandhir R.
    PLGA-based nanoparticles: a new paradigm in biomedical applications. Trac-Trend Anal Chem. 2016; 80: 30–40.
    OpenUrl
  79. 79.↵
    2. Fernandez-Piñeiro I,
    3. Badiola I,
    4. Sanchez A.
    Nanocarriers for microRNA delivery in cancer medicine. Biotechnol Adv. 2017; 35: 350–60.
    OpenUrlCrossRef
  80. 80.
    2. Zhang T,
    3. Xue X,
    4. He D,
    5. Hsieh JT.
    A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA. Cancer Lett. 2015; 365: 156–65.
    OpenUrlCrossRef
  81. 81.
    2. Debnath S,
    3. Karan S,
    4. Debnath M,
    5. Dash J,
    6. Chatterjee TK.
    Poly-L-lysine inhibits tumor angiogenesis and induces apoptosis in ehrlich ascites carcinoma and in sarcoma S-180 tumor. Asian Pac J Cancer Prev. 2017; 18: 2255–68.
    OpenUrl
  82. 82.
    2. Shukla RS,
    3. Qin B,
    4. Cheng K.
    Peptides used in the delivery of small noncoding RNA. Mol Pharm. 2014; 11: 3395–408.
    OpenUrl
  83. 83.
    2. Jin H,
    3. Yu Y,
    4. Chrisler WB,
    5. Xiong Y,
    6. Hu D,
    7. Lei C.
    Delivery of microRNA-10b with polylysine nanoparticles for inhibition of breast cancer cell wound healing. Breast Cancer. 2012; 6: 9–19.
    OpenUrlPubMed
  84. 84.
    2. Li T,
    3. Meng Z,
    4. Zhu X,
    5. Gan H,
    6. Gu R,
    7. Wu Z, et al.
    New synthetic peptide with efficacy for heparin reversal and low toxicity and immunogenicity in comparison to protamine sulfate. Biochem Biophys Res Commun. 2015; 467: 497–502.
    OpenUrl
  85. 85.
    2. Yoo H,
    3. Mok H.
    Evaluation of multimeric siRNA conjugates for efficient protamine-based delivery into breast cancer cells. Arch Pharm Res. 2015; 38: 129–36.
    OpenUrlPubMed
  86. 86.↵
    2. Silva S,
    3. Almeida AJ,
    4. Vale N.
    Combination of cell-penetrating peptides with nanoparticles for therapeutic application: A review. Biomolecules. 2019; 9: 22.
    OpenUrl
  87. 87.↵
    2. Mcclorey G,
    3. Banerjee S.
    Cell-penetrating peptides to enhance delivery of oligonucleotide-based therapeutics. Biomedicines. 2018; 6: 51.
    OpenUrl
  88. 88.
    2. Oh B,
    3. Song H,
    4. Lee D,
    5. Oh J,
    6. Kim G,
    7. Ihm SH, et al.
    Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucleotide in a glioblastoma animal model. J Drug Target. 2017; 25: 132–9.
    OpenUrl
  89. 89.
    2. Song H,
    3. Oh B,
    4. Choi M,
    5. Oh J,
    6. Lee M.
    Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy. J Drug Target. 2015; 23: 360–70.
    OpenUrl
  90. 90.
    2. Takei Y,
    3. Takigahira M,
    4. Mihara K,
    5. Tarumi Y,
    6. Yanagihara K.
    The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res. 2011; 71: 1442–53.
    OpenUrlAbstract/FREE Full Text
  91. 91.
    2. Takeshita F,
    3. Patrawala L,
    4. Osaki M,
    5. Takahashi RU,
    6. Yamamoto Y,
    7. Kosaka N, et al.
    Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2010; 18: 181–7.
    OpenUrlCrossRefPubMedWeb of Science
  92. 92.
    2. Tazawa H,
    3. Tsuchiya N,
    4. Izumiya M,
    5. Nakagama H.
    Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 2007; 104: 15472–7.
    OpenUrlAbstract/FREE Full Text
  93. 93.
    2. Ben-Shushan D,
    3. Markovsky E,
    4. Gibori H,
    5. Triam G,
    6. Scomparin A,
    7. Satchi-Fainaro R.
    Overcoming obstacles in microRNA delivery towards improved cancer therapy. Drug Deliv Transl Res. 2014; 4: 38–49.
    OpenUrl
  94. 94.
    2. Di Pietro P,
    3. Strano G,
    4. Zuccarello L,
    5. Satriano C.
    Gold and silver nanoparticles for applications in theranostics. Curr Top Med Chem. 2016; 16: 3069–102.
    OpenUrl
  95. 95.
    2. Vallet-Regí M,
    3. Colilla M,
    4. Izquierdo-Barba I,
    5. Manzano M.
    Mesoporous silica nanoparticles for drug delivery: current insights. Molecules. 2017; 23: 47.
    OpenUrl
  96. 96.
    2. El-Boubbou K.
    Magnetic iron oxide nanoparticles as drug carriers: clinical relevance. Nanomedicine. 2018; 13: 953–71.
    OpenUrl
  97. 97.
    2. Zhao MX,
    3. Zhu BJ.
    The research and applications of quantum dots as nano-carriers for targeted drug delivery and cancer therapy. Nanoscale Res Lett. 2016; 11: 207.
    OpenUrl
  98. 98.
    2. Li JM,
    3. Zhao MX,
    4. Su H,
    5. Wang YY,
    6. Tan CP,
    7. Ji LN, et al.
    Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging. Biomaterials. 2011; 32: 7978–87.
    OpenUrlCrossRefPubMedWeb of Science
  99. 99.
    2. Choi AO,
    3. Brown SE,
    4. Szyf M,
    5. Maysinger D.
    Quantum dot-induced epigenetic and genotoxic changes in human breast cancer cells. J Mol Med (Berl). 2008; 86: 291–302.
    OpenUrlCrossRefPubMed
  100. 100.
    2. Dobrovolskaia MA,
    3. Mcneil SE.
    Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007; 2: 469–78.
    OpenUrlCrossRefPubMedWeb of Science
  101. 101.
    2. Valentini F,
    3. Mari E,
    4. Zicari A,
    5. Calcaterra A,
    6. Talano M,
    7. Scioli MG, et al.
    Metal free graphene oxide (GO) nanosheets and pristine-single wall carbon nanotubes (p-SWCNTs) biocompatibility investigation: A comparative study in different human cell lines. Int J Mol Sci. 2018; 19: 1316.
    OpenUrl
  102. 102.
    2. Yang HW,
    3. Huang CY,
    4. Lin CW,
    5. Liu HL,
    6. Huang CW,
    7. Liao SS, et al.
    Gadolinium-functionalized nanographene oxide for combined drug and microRNA delivery and magnetic resonance imaging. Biomaterials. 2014; 35: 6534–42.
    OpenUrlCrossRef
  103. 103.
    2. Dahlin RL,
    3. Kasper FK,
    4. Mikos AG.
    Polymeric nanofibers in tissue engineering. Tissue Eng Part B Rev. 2011; 17: 349–64.
    OpenUrlCrossRefPubMedWeb of Science
  104. 104.
    2. Estanqueiro MVH,
    3. Lobo JMS,
    4. Amaral H
    2. Grumezescu AM.
    Delivering miRNA modulators for cancer treatment. In: Estanqueiro MVH, Lobo JMS, Amaral H. Drug targeting and stimuli sensitive drug delivery systems. London: William Andrew Publishing. 2018: 517–65.
  105. 105.
    2. Agrahari V,
    3. Agrahari V,
    4. Meng J,
    5. Mitra AK
    2. Mitra AK,
    3. Cholkar K,
    4. Mandal A.
    Electrospun Nanofibers in Drug Delivery: Fabrication, Advances, and Biomedical Applications. In: Agrahari V, Agrahari V, Meng J, Mitra AK, editors. Emerging nanotechnologies for diagnostics, drug delivery and medical devices. Amsterdam: Elsevier; 2017. p. 189–215.
  106. 106.
    2. Shi X,
    3. Zhou W,
    4. Ma D,
    5. Ma Q,
    6. Bridges D,
    7. Ma Y, et al.
    Ectrospinning of nanofibers and their applications for energy devices. J Nanomat. 2015; 16: 1–21.
    OpenUrl
  107. 107.
    2. Sasikanth K,
    3. Nama S,
    4. Suresh S,
    5. Brahmaiah B.
    Nanofibers-a new trend in nano drug delivery systems. Pharma Innovation. 2013; 2: 118.
    OpenUrl
  108. 108.
    2. Orellana EA,
    3. Tenneti S,
    4. Rangasamy L,
    5. Lyle LT,
    6. Low PS,
    7. Kasinski AL.
    FolamiRs: ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer. Sci Transl Med. 2017; 9: 1–10.
    OpenUrlCrossRefPubMed
  109. 109.↵
    2. He F,
    3. Wen N,
    4. Xiao D,
    5. Yan J,
    6. Xiong H,
    7. Cai S, et al.
    Aptamer-based targeted drug deliverysystems: Current potential and challenges. Curr Med Chem. 2020; 27: 2189–219.
    OpenUrl
  110. 110.
    2. Esposito CL,
    3. Catuogno S,
    4. de Franciscis V.
    Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells. J RNAi Gene Silencing. 2014; 10: 500–6.
    OpenUrlPubMed
  111. 111.↵
    2. Yin H,
    3. Xiong G,
    4. Guo S,
    5. Xu C,
    6. Xu R,
    7. Guo P, et al.
    Delivery of anti-miRNA for triple-negative breast cancer therapy using RNA nanoparticles targeting sem cell marker CD133. Mol Ther. 2019; 27: 1252–61.
    OpenUrlCrossRef
  112. 112.
    2. Guo S,
    3. Huang F,
    4. Guo P.
    Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther. 2006; 13: 814–20.
    OpenUrlPubMedWeb of Science
  113. 113.
    2. Ye X,
    3. Liu Z,
    4. Hemida MG,
    5. Yang D.
    Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA. PLoS One. 2011; 6: e21215.
  114. 114.↵
    2. Kovacevic AB
    2. Shegokar R.
    Lipid nanocarriers for delivery of poorly soluble and poorly permeable drugs. In: Kovacevic AB, editor. Nanopharmaceuticals. Amsterdam: Elsevier; 2020. p. 151–74.
  115. 115.↵
    2. Khalil IA,
    3. Younis MA,
    4. Kimura S,
    5. Harashima H.
    Lipid nanoparticles for cell-specific in vivo targeted delivery of nucleic acids. Biol Pharm Bull. 2020; 43: 584–95.
    OpenUrl
  116. 116.
    2. Costa PM,
    3. Cardoso AL,
    4. Custódia C,
    5. Cunha P,
    6. de Almedia LP,
    7. de Lima MC.
    MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. J Control Release. 2015; 207: 31–9.
    OpenUrl
  117. 117.↵
    2. Schlich M,
    3. Palomba R,
    4. Costabile G,
    5. Mizrahy S,
    6. Pannuzzo M,
    7. Peer D, et al.
    Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng Transl Med. 2021; 6: e10213.
  118. 118.↵
    2. Wei P,
    3. Cornel EJ,
    4. Du J.
    Ultrasound-responsive polymer-based drug delivery systems. Drug Deliv Transl Res. 2021; 11: 1323–39.
    OpenUrl
  119. 119.↵
    2. Dzmitruk V,
    3. Apartsin E,
    4. Ihnatsyeu-Kachan A,
    5. Abashkin V,
    6. Scharbin D,
    7. Bryszewska M.
    Dendrimers show promise for siRNA and microRNA therapeutics. Pharmaceutics. 2018; 10: 126.
    OpenUrl
  120. 120.↵
    2. Yazdian-Robati R,
    3. Ramezani M,
    4. Jalalian SH,
    5. Abnous K,
    6. Taghdisi SM.
    Targeted delivery of epirubicin to cancer cells by polyvalent aptamer system in vitro and in vivo. Pharm Res. 2016; 33: 2289–97.
    OpenUrl
  121. 121.↵
    2. Hao Y,
    3. Kieft JS.
    Three-way junction conformation dictates self-association of phage packaging RNAs. RNA Biol. 2016; 13: 635–45.
    OpenUrl
  122. 122.↵
    2. Hao C,
    3. Li X,
    4. Tian C,
    5. Jiang W,
    6. Wang G,
    7. Mao C.
    Construction of RNA nanocages by re-engineering the packaging RNA of Phi29 bacteriophage. Nat Commun. 2014; 5: 3890.
    OpenUrl
  123. 123.↵
    2. Binzel DW,
    3. Shu Y,
    4. Li H,
    5. Sun M,
    6. Zhang Q,
    7. Shu D, et al.
    Specific delivery of miRNA for high efficient inhibition of prostate cancer by RNA nanotechnology. Mol Ther. 2016; 24: 1267–77.
    OpenUrl
  124. 124.↵
    2. Mahato M,
    3. Jayandharan GR,
    4. Vemula PK
    2. Jayandharan GR.
    Viral-and non-viral-based hybrid vectors for gene therapy. In: Mahato M, Jayandharan GR, Vemula PK, editors. Gene and cell therapy: biology and applications. New York: Springer; 2018. p. 111–30.
  125. 125.↵
    2. Dasgupta I,
    3. Chatterjee A.
    Recent advances in miRNA delivery systems. Methods Protoc. 2021; 4: 10.
    OpenUrl
  126. 126.↵
    2. Frank AM,
    3. Weidner T,
    4. Brynza J,
    5. Uckert W,
    6. Buchholz CJ,
    7. Hartmann J.
    CD8-Specific designed ankyrin repeat proteins improve selective gene delivery into human and primate T lymphocytes. Hum Gene Ther. 2020; 31: 679–91.
    OpenUrl
  127. 127.↵
    2. Stein S,
    3. Ott MG,
    4. Schultze-Strasser S,
    5. Jauch A,
    6. Burwinkel B,
    7. Kinner A, et al.
    Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010; 16: 198–204.
    OpenUrlCrossRefPubMedWeb of Science
  128. 128.
    2. Hacein-Bey-Abina S,
    3. von Kalle C,
    4. Schmidt M,
    5. Le Deist F,
    6. Wulffraat N,
    7. Mclntyre E, et al.
    A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003; 348: 255–6.
    OpenUrlCrossRefPubMedWeb of Science
  129. 129.↵
    2. Cavazzana-Calvo M,
    3. Payen E,
    4. Negre O,
    5. Wang G,
    6. Hehir K,
    7. Fusil F, et al.
    Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010; 467: 318–22.
    OpenUrlCrossRefPubMedWeb of Science
  130. 130.↵
    2. Zhang JH,
    3. Du AL,
    4. Wang L,
    5. Wang XY,
    6. Gao JH,
    7. Wang TY.
    Episomal lentiviral vector-mediated miR-145 overexpression inhibits proliferation and induces apoptosis of human esophageal carcinomas cells. Recent Pat Anticancer Drug Discov. 2016; 11: 453–60.
    OpenUrl
  131. 131.↵
    2. Aravalli RN.
    Development of microRNA therapeutics for hepatocellular carcinoma. Diagnostics (Basel). 2013; 3: 170–91.
    OpenUrl
  132. 132.↵
    2. Bofill-De Ros X,
    3. Gironella M,
    4. Fillat C.
    MiR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity. Mol Ther. 2014; 22: 1665–77.
    OpenUrl
  133. 133.↵
    2. Kim J,
    3. Kim PH,
    4. Kim SW,
    5. Yun CO.
    Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials. 2012; 33: 1838–50.
    OpenUrl
  134. 134.↵
    2. Shams S,
    3. Silva EA
    2. Fernandes TG,
    3. Diogo MM,
    4. Cabral JMS.
    Bioengineering strategies for gene delivery. In: Shams S, Silva EA, editors. Engineering strategies for regenerative medicine. Academic Press; 2020. p. 107–48.
  135. 135.↵
    2. Aponte-Ubillus JJ,
    3. Barajas D,
    4. Peltier J,
    5. Bardliving C,
    6. Shamlou P,
    7. Gold D.
    Molecular design for recombinant adeno-associated virus (rAAV) vector production. Appl Microbiol Biotechnol. 2018; 102: 1045–54.
    OpenUrl
  136. 136.↵
    2. Latronico MV,
    3. Condorelli G.
    Therapeutic use of microRNAs in myocardial diseases. Curr Heart Fail Rep. 2011; 8: 193–7.
    OpenUrlCrossRefPubMed
  137. 137.↵
    2. Brunetti-Pierri N.
    AAV vector-based gene therapy, progress and current challenges. In Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders. New York: Springer; 2017. p. 77–112.
  138. 138.↵
    2. Vannucci L,
    3. Lai M,
    4. Chiuppesi F,
    5. Ceccherini-Nelli L,
    6. Pistello M.
    Viral vectors: a look back and ahead on gene transfer technology. New Microbiol. 2013; 36: 1–22.
    OpenUrlPubMed
  139. 139.↵
    2. Bhere D,
    3. Tamura K,
    4. Wakimoto H,
    5. Choi SH,
    6. Purow B,
    7. Debatisse J, et al.
    MicroRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro Oncol. 2018; 20: 215–24.
    OpenUrl
  140. 140.↵
    2. Saha G,
    3. Saudagar P,
    4. Dubey VK
    2. Sonawane SH,
    3. Bhanvase BA,
    4. Sivakumar M.
    Virus-like particles: nano-carriers in targeted therapeutics. In: Saha G, Saudagar P, Dubey VK, editors. Encapsulation of active molecules and their delivery system. Amsterdam: Elsevier; 2020. p. 197.
  141. 141.
    2. Yao Y,
    3. Jia T,
    4. Pan Y,
    5. Gou H,
    6. Li Y,
    7. Sun Y, et al.
    Using a novel microRNA delivery system to inhibit osteoclastogenesis. Int J Mol Sci. 2015; 16: 8337–50.
    OpenUrl
  142. 142.↵
    2. Pushko P,
    3. Pumpens P,
    4. Grens E.
    Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology. 2013; 56: 141–65.
    OpenUrlCrossRefPubMed
  143. 143.↵
    2. Callanan J,
    3. Stockdale SR,
    4. Shkoporov A,
    5. Draper LA,
    6. Ross RP,
    7. Hill C.
    RNA phage biology in a metagenomic era. Viruses. 2018; 10: 386.
    OpenUrl
  144. 144.↵
    2. Pinto AM,
    3. Silva MD,
    4. Pastrana LM,
    5. Bañobre-López M,
    6. Sillankorva S.
    The clinical path to deliver encapsulated phages and lysins. FEMS Microbiol Rev. Published online first: March 30, 2021. DOI: 10.1093/femsre/fuab019.
    OpenUrlCrossRef
  145. 145.↵
    2. Dashti NH,
    3. Sainsbury F
    2. Gerrard JA,
    3. Domigan LJ.
    Virus-derived nanoparticles. In: Dashti NH, Sainsbury F, editors. Protein nanotechnology. New York: Springer; 2020. p. 149–62.
  146. 146.↵
    2. Pan Y,
    3. Zhang Y,
    4. Jia T,
    5. Zhang K,
    6. Li J,
    7. Wang L.
    Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J. 2012; 279: 1198–208.
    OpenUrlCrossRefPubMed
  147. 147.↵
    2. Sun Y,
    3. Sun Y,
    4. Zhao R.
    Establishment of microRNA delivery system by PP7 bacteriophage-like particles carrying cell-penetrating peptide. J Biosci Bioeng. 2017; 124: 242–9.
    OpenUrl
  148. 148.↵
    2. Hoffmann DB,
    3. Böker KO,
    4. Schneider S,
    5. Eckermann-Felkl E,
    6. Schuder A,
    7. Komrakova M, et al.
    In vivo siRNA delivery using JC virus-like particles decreases the expression of RANKL in rats. Mol Ther Nucleic Acids. 2016; 5: e298.
  149. 149.↵
    2. Chao CN,
    3. Yang YH,
    4. Wu MS,
    5. Chou MC,
    6. Fang CY,
    7. Lin MC, et al.
    Gene therapy for human glioblastoma using neurotropic JC virus-like particles as a gene delivery vector. Sci Rep. 2018; 8: 2213.
    OpenUrl
  150. 150.↵
    2. Chen W,
    3. Kang T,
    4. Yuan R,
    5. Shao C,
    6. Jing S.
    Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine. Biotechnol Lett. 2020; 42: 1211–8.
    OpenUrl
  151. 151.
    2. Armstrong JK,
    3. Hempel G,
    4. Koling S,
    5. Chan LS,
    6. Fisher T,
    7. Meiselman HJ, et al.
    Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007; 110: 103–11.
    OpenUrlCrossRefPubMedWeb of Science
  152. 152.↵
    2. Galaway FA,
    3. Stockley PG.
    MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform. Mol Pharm. 2013; 10: 59–68.
    OpenUrlCrossRefPubMed
  153. 153.↵
    2. Lin Y,
    3. Lu Y,
    4. Li X.
    Biological characteristics of exosomes and genetically engineered exosomes for the targeted delivery of therapeutic agents. J Drug Target. 2020; 28: 129–41.
    OpenUrl
  154. 154.
    2. Sun Z,
    3. Shi K,
    4. Yang S,
    5. Liu J,
    6. Zhou Q,
    7. Wang G, et al.
    Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018; 17: 147.
    OpenUrlCrossRef
  155. 155.↵
    2. del Pozo-Acebo L,
    3. Hazas MLL,
    4. Tomé-Carneiro J,
    5. Gil-Cabrerizo P,
    6. San-Cristobal R,
    7. Busto R, et al.
    Bovine milk-derived exosomes as a drug delivery vehicle for miRNA-based therapy. Int J Mol Sci. 2021; 22: 1105.
    OpenUrl
  156. 156.↵
    2. Shimbo K,
    3. Miyaki S,
    4. Ishitobi H,
    5. Kato Y,
    6. Kubo T,
    7. Shimose S, et al.
    Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem Biophys Res Commun. 2014; 445: 381–7.
    OpenUrlCrossRefPubMed
  157. 157.↵
    2. Ohno S,
    3. Takanashi M,
    4. Sudo K,
    5. Ueda S,
    6. Ishikawa A,
    7. Matsuyama N, et al.
    Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013; 21: 185–91.
    OpenUrlCrossRefPubMed
  158. 158.↵
    2. Wang Y,
    3. Chen X,
    4. Tian B,
    5. Liu J,
    6. Yang L,
    7. Zeng L, et al.
    Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer. Theranostics. 2017; 7: 1360–72.
    OpenUrl
  159. 159.↵
    2. Lu M,
    3. Xing H,
    4. Xun Z,
    5. Yang T,
    6. Ding P,
    7. Cai C, et al.
    Exosome-based small RNA delivery: progress and prospects. Asian J Pharm Sci. 2018; 13: 1–11.
    OpenUrl
  160. 160.
    2. Morishita M,
    3. Takahashi Y,
    4. Nishikawa M,
    5. Sano K,
    6. Kato K,
    7. Yamashita T, et al.
    Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin-lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice. J Pharm Sci. 2015; 104: 705–13.
    OpenUrlCrossRefPubMed
  161. 161.↵
    2. Takahashi Y,
    3. Nishikawa M,
    4. Shinotsuka H,
    5. Matsui Y,
    6. Ohara S,
    7. Imai T, et al.
    Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol. 2013; 165: 77–84.
    OpenUrlCrossRefPubMedWeb of Science
  162. 162.↵
    2. Pittenger MF,
    3. Discher DE,
    4. Péault BM,
    5. Phinney DG,
    6. Hare JM,
    7. Caplan AI.
    Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019; 4: 22.
    OpenUrl
  163. 163.
    2. Korsgren O,
    3. Scholz H
    2. Orlando G,
    3. Piemonti L,
    4. Ricordi C,
    5. Stratta RJ
    , eds. Cellular therapies in preclinical and clinical islet transplantation: Mesenchymal stem cells. In: Korsgren O, Scholz H, editors. Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas. Cambridge: Academic Press; 2020. p. 821–31.
  164. 164.↵
    2. Su Y,
    3. Zhang T,
    4. Huang T,
    5. Gao J.
    Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements. Int J Pharm. 2021; 600: 120477.
  165. 165.↵
    2. Fan XL,
    3. Zhang Y,
    4. Li X,
    5. Fu QL.
    Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020; 77: 2771–94.
    OpenUrlCrossRefPubMed
  166. 166.↵
    2. Shah K.
    Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev. 2012; 64: 739–48.
    OpenUrlCrossRefPubMed
  167. 167.↵
    2. Munoz JL,
    3. Bliss SA,
    4. Greco SJ,
    5. Ramkissoon SH,
    6. Ligon KL,
    7. Rameshwar P.
    Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids. 2013; 2: e126.
  168. 168.↵
    2. Lee HK,
    3. Finniss S,
    4. Cazacu S,
    5. Bucris E,
    6. Ziv-Av A,
    7. Xiang C, et al.
    Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013; 4: 346–61.
    OpenUrlCrossRefPubMed
  169. 169.↵
    2. Zhang CL,
    3. Huang T,
    4. Wu BL,
    5. He WX,
    6. Liu D.
    Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017; 8: 75756–66.
    OpenUrlCrossRef
  170. 170.↵
    2. Chu DT,
    3. Nguyen TT,
    4. Tien NLB,
    5. Tran DK,
    6. Jeong JH,
    7. Anh PG, et al.
    Recent progress of stem cell therapy in cancer treatment: molecular mechanisms and potential applications. Cells. 2020; 9: 563.
    OpenUrl
  171. 171.↵
    2. Bonneau E,
    3. Neveu B,
    4. Kostantin E,
    5. Tsongalis GJ,
    6. de Guire V.
    How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. EJIFCC. 2019; 30: 114–27.
    OpenUrlPubMed
  172. 172.↵
    2. Baumann V,
    3. Winkler J.
    miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem. 2014; 6: 1967–84.
    OpenUrlCrossRefPubMed
  173. 173.↵
    2. Beg MS,
    3. Brenner AJ,
    4. Sachdev J,
    5. Borad M,
    6. Kang YK,
    7. Stoudemire J, et al.
    Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017; 35: 180–8.
    OpenUrlCrossRefPubMed
  174. 174.↵
    2. Hong DS,
    3. Kang YK,
    4. Borad M,
    5. Sachdev J,
    6. Ejadi S,
    7. Lim HY, et al.
    Phase I study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122: 1630–7.
    OpenUrlCrossRefPubMed
  175. 175.↵
    2. Titze-De-Almeida R,
    3. David C,
    4. Titze-De-Almeida SS.
    The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res. 2017; 34: 1339–63.
    OpenUrl
  176. 176.↵
    2. Kreth S,
    3. Hübner M,
    4. Hinske LC.
    MicroRNAs as clinical biomarkers and therapeutic tools in perioperative medicine. Anesth Analg. 2018; 126: 670–81.
    OpenUrl
  177. 177.↵
    2. Reid G,
    3. Johnson TG,
    4. van Zandwijk N.
    Manipulating microRNAs for the treatment of malignant pleural mesothelioma: Past, present and future. Front Oncol. 2020; 10: 105.
    OpenUrlCrossRefPubMed
  178. 178.↵
    2. van Zandwijk N,
    3. Pavlakis N,
    4. Kao SC,
    5. Linton A,
    6. Boyer MJ,
    7. Clarke S, et al.
    Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase I, open-label, dose-escalation study. Lancet Oncol. 2017; 18: 1386–96.
    OpenUrlCrossRefPubMed
  179. 179.↵
    2. Bajan S,
    3. Hutvagner G.
    RNA-based therapeutics: From antisense oligonucleotides to miRNAs. Cells. 2020; 9: 137.
    OpenUrl
  180. 180.↵
    2. Shah MY,
    3. Ferrajoli A,
    4. Sood AK,
    5. Lopez-Berestein G,
    6. Calin GA.
    MicroRNA therapeutics in cancer - an emerging concept. EBioMedicine. 2016; 12: 34–42.
    OpenUrl
  181. 181.↵
    2. Souckova K,
    3. Ivkovic TC,
    4. Slaby O
    2. Faintuch J,
    3. Faintuch S.
    Non-coding RNA therapy in cancer. In: Souckova K, Ivkovic TC, Slaby O, editors. Precision medicine for investigators, practitioners and providers. Cambridge: Academic Press; 2020. p. 211–20.
  182. 182.↵
    2. Segal M,
    3. Biscans A,
    4. Gilles ME,
    5. Anastasiadou E,
    6. de Luca R,
    7. Lim J, et al.
    Hydrophobically modified let-7b miRNA enhances biodistribution to NSCLC and downregulates HMGA2 in vivo. Mol Ther Nucleic Acids. 2020; 19: 267–77.
    OpenUrl
  183. 183.↵
    2. Hossian A,
    3. Mackenzie GG.
    Mattheolabakis G. MiRNAs in gastrointestinal diseases: can we effectively deliver RNA-based therapeutics orally? Nanomedicine (Lond). 2019; 14: 2873–89.
    OpenUrl
  184. 184.↵
    2. Tao H,
    3. Zhao J,
    4. Liu T,
    5. Cai Y,
    6. Zhou X,
    7. Xing H, et al.
    Intranasal delivery of miR-146a mimics delayed seizure onset in the lithium-pilocarpine mouse model. Mediators Inflamm. 2017; 2017: 6512620.
  185. 185.↵
    2. Topcu B,
    3. Gultekinoglu M,
    4. Timur SS,
    5. Eroglu I,
    6. Ulubayram K,
    7. Eroglu H.
    Current approaches and future prospects of nanofibers: a special focus on antimicrobial drug delivery. J Drug Target. 2021; 29: 563–75.
    OpenUrl
  186. 186.↵
    2. Wang G,
    3. Hu W,
    4. Chen H,
    5. Shou X,
    6. Ye T,
    7. Xu Y.
    Cocktail strategy based on NK cell-derived exosomes and their biomimetic nanoparticles for dual tumor therapy. Cancers (Basel). 2019; 11: 1560.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords